Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
Journal of Clinical Investigation · 2023
DOI: 10.1172/jci166844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Siriruk Changrob und 26 weiteren Autor:innen. Beteiligte Einrichtung: Drukier Institute for Children's Health, Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has emphasized the need to identify antibodies with broad neutralizing capabilities to inform future monoclonal therapies and vaccination strategies. Herein, we identified S728-1157, a broadly neutralizing antibody (bnAb) targeting the receptor-binding site (RBS) that was derived from an individual previously infected with WT SARS-CoV-2 prior to the spread of variants of concern (VOCs). S728-1157 demonstrated broad cross-neutralization of all dominant variants, including D614G, Beta, Delta, Kappa, Mu, and Omicron (BA.1/BA.2/BA.2.75/BA.4/BA.5/BL.1/XBB). Furthermore, S728-1157 protected hamsters against in vivo challenges with WT, Delta, and BA.1 viruses. Structural analysis showed that this antibody targets a class 1/RBS-A epitope in the receptor binding domain via multiple hydrophobic and polar interactions with its heavy chain complementarity determining region 3 (CDR-H3), in addition to common motifs in CDR-H1/CDR-H2 of class 1/RBS-A antibodies. Importantly, this epitope was more readily accessible in the open and prefusion state, or in the hexaproline (6P)-stabilized spike constructs, as compared with diproline (2P) constructs. Overall, S728-1157 demonstrates broad therapeutic potential and may inform target-driven vaccine designs against future SARS-CoV-2 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drukier Institute for Children's Health, Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
- Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
- University of Chicago Department of Medicine, Section of Rheumatology, Chicago, Illinois, USA.
- Department of Pathology, Molecular and Cell Based Medicine.
- Department of Microbiology.
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIAID Centers of Excellence for Influenza Research and Surveillance
- NIAD Centers of Excellence for Influenza Research and Response
- Research Program on Emerging and Re-emerging Infectious Diseases
- Japan Agency for Medical Research and Development
- BEI/NIAID
Zitieren
APA
Changrob, S., Halfmann, P. J., Liu, H., Torres, J. L., McGrath, J. J. C., Ozorowski, G., Li, L., Wilbanks, G. D., Kuroda, M., Maemura, T., Huang, M., Zheng, N. Y., Turner, H. L., Erickson, S. A., Fu, Y., Yasuhara, A., Singh, G., Monahan, B., Mauldin, J., …, & Wilson, P. C. (2023). Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. Journal of Clinical Investigation. https://doi.org/10.1172/jci166844
Vancouver
Changrob S, Halfmann PJ, Liu H, Torres JL, McGrath JJC, Ozorowski G, et al. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. Journal of Clinical Investigation. 2023. doi:10.1172/jci166844
BibTeX
@article{Changrob2023,
author = {Changrob, Siriruk and Halfmann, Peter J and Liu, Hejun and Torres, Jonathan L and McGrath, Joshua J C and Ozorowski, Gabriel and Li, Lei and Wilbanks, G Dewey and Kuroda, Makoto and Maemura, Tadashi and Huang, Min and Zheng, Nai-Ying and Turner, Hannah L and Erickson, Steven A and Fu, Yanbin and Yasuhara, Atsuhiro and Singh, Gagandeep and Monahan, Brian and Mauldin, Jacob and Srivastava, Komal and Simon, Viviana and Krammer, Florian and Sather, D Noah and Ward, Andrew B and Wilson, Ian A and Kawaoka, Yoshihiro and Wilson, Patrick C},
title = {Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants},
journal = {Journal of Clinical Investigation},
year = {2023},
doi = {10.1172/jci166844}
}
EUVIMED